Exagen Inc. (XGN)
| Market Cap | 180.48M -30.2% |
| Revenue (ttm) | 71.12M +20.8% |
| Net Income | -18.92M |
| EPS | -0.80 |
| Shares Out | 24.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 106,758 |
| Open | 7.20 |
| Previous Close | 7.27 |
| Day's Range | 7.05 - 7.59 |
| 52-Week Range | 2.59 - 12.23 |
| Beta | 2.12 |
| Analysts | Strong Buy |
| Price Target | 10.57 (+41.88%) |
| Est. Earnings | Nov 6, 2026 |
About XGN
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company’s lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CT... [Read more]
Financial Performance
In 2025, Exagen's revenue was $66.58 million, an increase of 19.65% compared to the previous year's $55.64 million. Losses were -$19.95 million, 32.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for XGN stock is "Strong Buy." The 12-month stock price target is $10.57, which is an increase of 41.88% from the latest price.
News
Exagen price target raised to $11 from $9 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Exagen (XGN) to $11 from $9 and keeps a Buy rating on the shares. The firm updated its model ahead…
Exagen price target raised to $11 from $10 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Exagen (XGN) to $11 from $10 and keeps a Buy rating on the shares. The firm adjusted targets in…
Exagen transferred with Buy rating at B. Riley
B. Riley kept a Buy rating on Exagen (XGN) with a $12 price target following a transfer of coverage. The firm views Exagen as a “self-funded diagnostics turnaround,” transitioning to…
Exagen participates in a conference call with Craig-Hallum
Craig-Hallum holds a conference call with management on September 2 at 2 pm hosted by Craig-Hallum. Webcast Link
Exagen Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company has significantly improved reimbursement rates and profitability by focusing on higher-quality test volume and operational efficiency. Product innovation continues with a new myositis test planned for 2027, while commercial expansion and R&D investment support long-term growth ambitions.
Exagen price target raised to $9 from $8 at BTIG
BTIG raised the firm’s price target on Exagen (XGN) to $9 from $8 and keeps a Buy rating on the shares. Exagen surged after a strong Q2 beat and raise,…
Exagen price target raised to $12 from $8 at B. Riley
B. Riley analyst Anderson Schock raised the firm’s price target on Exagen (XGN) to $12 from $8 and keeps a Buy rating on the shares. The firm cites higher estimates…
Exagen price target raised to $10 from $8 at TD Cowen
TD Cowen raised the firm’s price target on Exagen (XGN) to $10 from $8 and keeps a Buy rating on the shares. The firm said 2Q was solid with revenues…
Exagen price target raised to $9 from $8 at Canaccord
Canaccord raised the firm’s price target on Exagen (XGN) to $9 from $8 and keeps a Buy rating on the shares. The firm said the price target raise is driven…
Exagen raises FY26 revenue view to $72M-$75M from $70M-$73M
Consensus $71.67M. The company said, “The Company increased full-year 2026 revenue guidance to $72 million – $75 million compared to previous guidance of $70 million – $73 million.” Published first…
Exagen reports Q2 EPS (13c), consensus (17c)
Reports Q2 revenue $19.94M, consensus $17.87M. “We continue to advance Exagen’s (XGN) unique mission to bring clarity to autoimmune disease,” said John Aballi, President and Chief Executive Officer. “...
Exagen Earnings Call Transcript: Q2 2026
Record revenue and test volumes drove a 16% year-over-year increase, with adjusted EBITDA near break-even. Full-year guidance was raised, gross margin improved, and Pharma Services revenue more than doubled. Myositis product launch remains on track for early 2027.
Exagen Earnings release: Q2 2026
Exagen released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Exagen Slides: Q2 2026
Exagen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Exagen Quarterly report: Q2 2026
Exagen has published its Q2 2026 quarterly earnings report on August 4, 2026.
Exagen Inc. Reports Second Quarter 2026 Financial Results
Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - ...
Exagen Inc. to Participate in Upcoming Investor Conference
CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conf...
Exagen to Announce Second Quarter Financial Results on August 4, 2026
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, ...
Roth starts Exagen at Buy, notes biomarker testing outperformance
Roth Capital analyst Max Masucci initiated coverage of Exagen (XGN) with a Buy rating and $8 price target Exagen’s autoimmune testing portfolio, headlined by its AVISE CTD test, faces no…
Exagen initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Exagen (XGN) with a Buy rating and $8 price target
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, mor...
Exagen price target lowered to $8 from $9 at BTIG
BTIG lowered the firm’s price target on Exagen (XGN) to $8 from $9 and keeps a Buy rating on the shares. The company delivered a 5% revenue beat in Q1…
Exagen reports Q1 EPS (17c), consensus (25c)
Reports Q1 revenue $17.31M, consensus $16.41M. “First quarter results establish a solid start to 2026, reflecting our team’s disciplined execution and effective revenue cycle management,” said John Ab...
Exagen backs FY26 revenue view $70M-$73M, consensus $71.27M
The company said, “The Company continues to expect full-year 2026 revenue of $70 million to $73 million.”
Exagen Earnings Call Transcript: Q1 2026
Record Q1 2026 revenue grew 12% year-over-year, with gross margin at 59% and improved profitability. Test volume and ASP both increased, and full-year guidance was reaffirmed. Commercial expansion and innovation continue to drive growth.